Researchers track IBRANCE® safety in korean breast cancer patients
NCT ID NCT03445637
First seen Jan 09, 2026 · Last updated Jun 14, 2026 · Updated 27 times
Summary
This study looked at the safety and effectiveness of the drug IBRANCE® when used in everyday medical practice. It involved over 500 women in Korea with advanced or metastatic breast cancer. The main goal was to track any side effects during the first 3 months of treatment, as part of a long-term safety monitoring plan required by Korean health authorities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.